Cargando…
Treatment with soluble activin type IIB-receptor improves bone mass and strength in a mouse model of Duchenne muscular dystrophy
BACKGROUND: Inhibition of activin/myostatin pathway has emerged as a novel approach to increase muscle mass and bone strength. Duchenne muscular dystrophy (DMD) is a neuromuscular disorder that leads to progressive muscle degeneration and also high incidence of fractures. The aim of our study was to...
Autores principales: | Puolakkainen, Tero, Ma, Hongqian, Kainulainen, Heikki, Pasternack, Arja, Rantalainen, Timo, Ritvos, Olli, Heikinheimo, Kristiina, Hulmi, Juha J., Kiviranta, Riku |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5244551/ https://www.ncbi.nlm.nih.gov/pubmed/28103859 http://dx.doi.org/10.1186/s12891-016-1366-3 |
Ejemplares similares
-
Treatment with Soluble Activin Type IIB Receptor Ameliorates Ovariectomy-Induced Bone Loss and Fat Gain in Mice
por: Puolakkainen, Tero, et al.
Publicado: (2022) -
Soluble activin type IIB receptor improves fracture healing in a closed tibial fracture mouse model
por: Puolakkainen, Tero, et al.
Publicado: (2017) -
Activin Receptor Ligand Blocking and Cancer Have Distinct Effects on Protein and Redox Homeostasis in Skeletal Muscle and Liver
por: Hentilä, Jaakko, et al.
Publicado: (2019) -
Upregulation of activin-B and follistatin in pulmonary fibrosis – a translational study using human biopsies and a specific inhibitor in mouse fibrosis models
por: Myllärniemi, Marjukka, et al.
Publicado: (2014) -
Differentiation of Murine C2C12 Myoblasts Strongly Reduces the Effects of Myostatin on Intracellular Signaling
por: Lautaoja, Juulia H., et al.
Publicado: (2020)